AVRO News and Press, AVROBIO Inc. From 08/13/20

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

AVROBIO (NASDAQ: AVRO ) : Q2 GAAP EPS of -$0.80 misses by $0.02 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 a...

AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 1:10 p.m. ET on ...

Avrobio (NASDAQ: AVRO ) doses first patient in its Phase 1/2  GuardOne clinical trial , evaluating AVR-RD-02 for Gaucher disease type 1, an inherited disorder caused by the accumulation of a type of lipid in tissues due to the dysfunction in a certain enzyme. More news on: AVRO...

First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene ther...

AVROBIO co-founder and veteran gene and cell therapy pioneer Kim Warren to retire July 31, 2020 AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study for AVR-RD-03 for Pompe disease currently underway AVROBI...

Thinly traded AVROBIO (NASDAQ: AVRO ) jumps  4%  premarket on light volume in reaction to updated data  from a Phase 2 study evaluating its AVR-RD-01 gene therapy in patients with Fabry disease , an inherited disorder characterized by the buildup of a type of fat in the bo...